Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S‐1 for neoadjuvant therapy of locally advanced gastric cancer with HER2‐overexpressing: Preliminary results of a prospective, single‐arm, phase II study

Abstract Purpose Perioperative treatment of gastric and gastroesophageal junction (G/GEJ) cancer is evolving towards multimodal strategies incorporating HER2‐targeted therapy, immunotherapy and chemotherapy. Disitamab vedotin (RC48), an HER2‐targeted antibody–drug conjugate, shows promising antitumo...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Longgang Wang, Bing Liu, Luguang Liu, Liqing Liu, Rong Li, Shumei Han, Xu Sun, Bo Bi, Yuanlin Sun, Dong Sun, Jie Chai
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Wiley 2026-05-01
Sarja:	Clinical and Translational Medicine
Aiheet:	antibody‒drug conjugate disitamab vedotin G/GEJ cancer HER2‐overexpressing neoadjuvant therapy
Linkit:	https://doi.org/10.1002/ctm2.70679
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!